galanin


Also found in: Wikipedia.

galanin

[galan′in, gal′ənin]
a neuropeptide in the small intestine and central and peripheral nervous systems that has a role in bowel motility, pancreas activity, and prolactin and growth hormone release.

galanin

(găl′ăn-ĭn)
A peptide neurotransmitter with numerous functions in the central nervous system and the gastrointestinal tract. It stimulates gastrointestinal smooth muscle contraction and inhibits insulin secretion.
References in periodicals archive ?
We are extremely happy to have Warner-Lambert join us in our galanin program," said Kathleen P.
Galanin also helps control the release of insulin and stimulates brain messengers that reinforce eating.
ABSTRACT : The goal of this study was to determine whether galanin affects the mean plasma concentrations of metabolic parameters such as thyroxine (T4), triiodothyronine (T3), growth hormone (GH), insulin, glucagon, glucose, fatty acid and urea in goats fed diets differing in energy content.
Her studies in rats indicate that one of these chemicals, called neuropeptide Y, causes carbohydrate erarings, while the other, called galanin, seems to underlie a yen for fat.
A brain protein called galanin may dictate an individual's appetite for fat, neuroscientists reported (142: 311).
Leibowitz at Rockefeller University in New York City has uncovered evidence in rats that a brain protein called galanin dictates the craving for fatty foods.
Assistant Professor, Neurosurgery, Emory University, will be conducting preclinical studies of a Galanin gene delivery for selected patients with uncontrolled Mesial Temporal Lobe Epilepsy (MTLE).
His work on the design, synthesis and biochemical and pharmacological application of the first galanin antagonists was critical for the elucidation of the biological effects of galanin in depression, cognition and pain.
May 14 /PRNewswire/ -- Synaptic Pharmaceutical Corporation (Nasdaq: SNAP) today announced that its partner in the field of galanin drug discovery, Warner-Lambert Company, has decided not to enter into the second stage of the collaboration which began in July 1997.
Neurogen's AIDD(SM) program has produced NPY antagonists, including Neurogen's lead anti-obesity candidate NGD 95-1, which is in human clinical development; GLP1 agonists for type II diabetes; CRF agonists for obesity; CRF antagonists for stress and depression; and galanin antagonists for obesity, dementia and pain.
In addition, I am pleased that we continue to hold the confidence of the pharmaceutical giants and expand our corporate partner relationships, most recently regarding a galanin receptor collaboration with the Warner-Lambert Company.
In addition, AIDD has spawned multiple drug candidates in the Company's galanin, dopamine, GABA, CRF, and NPY programs.